|Bid||29.800 x 900|
|Ask||29.850 x 2900|
|Day's Range||29.575 - 30.150|
|52 Week Range||16.550 - 36.350|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 2, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||24.13|
Biotech stocks came under pressure earlier in the week, weighed down by negative trial results, mixed FDA verdicts and overall pessimistic broader market sentiment, but recovered in the last two sessions. ...
Acorda Therapeutics, Inc. (ACOR) will present four encore INBRIJA posters at the upcoming 2nd Pan American Parkinson’s Disease and Movement Disorders Congress taking place June 22-24, 2018 in Miami, Florida. INBRIJA is an investigational inhaled levodopa treatment for symptoms of OFF periods in people with Parkinson’s disease taking a carbidopa/levodopa regimen.
NEW YORK, NY / ACCESSWIRE / June 11, 2018 / Acorda Therapeutics was seeing big gains on Friday after Wall Street learned that the company's lawyers had try to save previously invalidated patents for its ...
Acorda (ACOR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Losses were broad based as eight out of nine sectors finished the trading session in red. WallStEquities.com has initiated research reports on the following Biotechnology stocks: ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Achaogen Inc. (NASDAQ: AKAO), Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), and Acorda Therapeutics Inc. (NASDAQ: ACOR).
LONDON, UK / ACCESSWIRE / June 1, 2018 / If you want access to our free research report on Gilead Sciences, Inc. (NASDAQ: GILD), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=GILD as the Company's latest news hit the wire. On May 30, 2018, the Company announced that the China Drug Administration (CDA) has approved Epclusa® for the treatment of adults with genotype 1-6 chronic hepatitis C virus (HCV) infection.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on May 29) Ascendis Pharma A/S (NASDAQ: ASN ) ASLAN PHARMACEUTICALS ...
Acorda Therapeutics, Inc. (ACOR) today announced that the European Medicines Agency (EMA) has completed formal validation of Acorda’s Marketing Authorization Application (MAA) for INBRIJA. INBRIJA is an investigational inhaled levodopa treatment for symptoms of OFF periods in people with Parkinson’s disease taking a carbidopa/levodopa regimen. The INBRIJA MAA was submitted to the EMA on March 23, 2018.
NEW YORK, May 15, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of First ...
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
The Ardsley, New York-based company said it had a loss of 18 cents per share. Earnings, adjusted for non-recurring costs and stock option expense, came to 14 cents per share. The results fell short of ...
Amicus Therapeutics (FOLD) is a global patient-focused biotechnology company engaged in developing and commercializing diverse novel treatments for patients with rare metabolic diseases. As of April 2018, of the seven analysts covering Amicus Therapeutics, three have given the stock “strong buy” ratings, three have given it “buy” ratings, and one has given it a “hold” rating. The mean rating for the stock is 1.71 with a target price of $19.93, implying an upside of almost 45% to $13.79 as of its closing on April 24.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding ACOR totaled $491 million.
Acorda Therapeutics, Inc. will present new data for INBRIJA during four oral platform presentations at the upcoming American Academy of Neurology Annual Meeting in Los Angeles, taking place April 21–27, 2018.
Regenxbio (RGNX) is a clinical-stage biotechnology company focused on developing gene therapy product candidates to address genetic defects. The company’s product candidate RGX-314 is designed for the treatment of wet age-related macular degeneration (or wet AMD), which is a leading cause of total and partial vision loss in the US, Europe, and Japan. The other promising product candidate in Regenxbio’s pipeline is RGX-501 for the treatment of homozygous familial hypercholesterolemia (or HoFH).
In fiscal 2017, Acorda Therapeutics (ACOR) generated $96.5 million from operating activities, compared with $35.3 million in fiscal 2016. Despite the significant growth of its net loss in fiscal 2017, the company generated positive operating cash flow, mainly due to $296.7 million in asset impairment charges and a $40.6 million change in contingent consideration obligations.